Pharmacoeconomic Comparison of Ziprasidone With Other Atypical Oral Antipsychotic Agents in Schizophrenia

Farmeconomia. Health economics and therapeutic pathways
doi 10.7175/fe.v12i1.96
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Seed SRL

Related search

Metabolomic Mapping of Atypical Antipsychotic Effects in Schizophrenia

Molecular Psychiatry
PsychiatryMolecular NeuroscienceMental HealthMolecular BiologyCellular
2007English

Measurement of Treatment Adherence With Antipsychotic Agents in Patients With Schizophrenia

Neuropsychiatric Disease and Treatment
PsychiatryMental HealthBiological Psychiatry
2009English

Chlorpromazine Versus Atypical Antipsychotic Drugs for Schizophrenia

2013English

Antipsychotic Monotherapy and Polypharmacy in the Naturalistic Treatment of Schizophrenia With Atypical Antipsychotics

BMC Psychiatry
PsychiatryMental Health
2005English

Ziprasidone vs Clozapine in Schizophrenia Patients Refractory to Multiple Antipsychotic Treatments: The MOZART Study

Schizophrenia Research
PsychiatryMental HealthBiological Psychiatry
2009English

Atypical Antipsychotic Agents, Retinopathy, Nephropathy, and Cardiovascular Disease

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2006English

Comparison of Antipsychotic Medication Effects on Reducing Violence in People With Schizophrenia

British Journal of Psychiatry
MedicinePsychiatryMental Health
2008English

Treatment Responses of Cognitive Function and Plasma Asymmetric Dimethylarginine to Atypical Antipsychotic in Patients With Schizophrenia

Frontiers in Psychiatry
PsychiatryMental Health
2019English

Switching From Oral Atypical Antipsychotic Monotherapy to Paliperidone Palmitate Once-Monthly in Non-Acute Patients With Schizophrenia: A Prospective, Open-Label, Interventional Study

Psychopharmacology
Pharmacology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy